Diagnosis of Cardiac Amyloidosis

Clinical Presentation and Diagnosis

• The American Heart Association recommends that the diagnosis of cardiac amyloidosis follows a structured pathway beginning with clinical suspicion based on red flags, followed by echocardiography as first-line imaging, then monoclonal protein screening to differentiate subtypes, and finally either nuclear imaging or cardiac MRI for confirmation—with biopsy reserved for equivocal cases 1, 2.
• The American Society of Nuclear Cardiology suggests that cardiac manifestations such as heart failure with preserved ejection fraction (HFpEF) with unexplained left ventricular wall thickness ≥12 mm should immediately trigger suspicion for cardiac amyloidosis 2.
• The American College of Cardiology notes that low QRS voltage on ECG despite ventricular wall thickening on imaging (voltage-to-mass discordance) is a specific finding for cardiac amyloidosis 3, 4, 2.
• Bilateral carpal tunnel syndrome without rheumatoid arthritis or trauma is an extracardiac red flag for cardiac amyloidosis, according to the American Heart Association 1, 2, 5.
• The European Society of Cardiology states that disproportionately elevated NT-proBNP or BNP relative to degree of heart failure (sensitivity 93%, specificity 90%) is a biomarker abnormality indicative of cardiac amyloidosis 4, 6, 2.

Diagnostic Imaging

• Echocardiography must be performed in all patients with suspected cardiac amyloidosis or systemic amyloidosis with heart failure, as recommended by the American Society of Echocardiography 3, 4, 2.
• The International Society for Heart Research notes that left ventricular wall thickness >12 mm with small cavity size is a key echocardiographic finding for cardiac amyloidosis 1, 2.
• Cardiac MRI should be performed when echocardiography shows suggestive but not definitive findings, according to the Society for Cardiovascular Magnetic Resonance 2.
• The American Heart Association recommends that cardiac MRI diagnostic features include LV wall thickness > upper limit of normal for sex on SSFP cine imaging, global extracellular volume (ECV) >0.40, and diffuse late gadolinium enhancement (LGE) 1, 2.

Biopsy and Histological Diagnosis

• Endomyocardial biopsy remains the definitive diagnostic test when non-invasive methods are equivocal or when precise tissue diagnosis is required, as stated by the American College of Cardiology 3, 6, 5.
• The European Society of Cardiology notes that Congo red staining showing apple-green birefringence under polarized light confirms amyloid, and mass spectrometry-based analysis (LC-MS/MS) is the gold standard for amyloid typing (88% sensitivity, 96% specificity) 1, 3, 6, 5.

Diagnostic Pitfalls and Integration of Modalities

• The American Heart Association warns against relying solely on clinical features without histological or imaging confirmation when monoclonal gammopathy is present—not all monoclonal proteins indicate AL amyloidosis 5.
• The American Society of Nuclear Cardiology advises against assuming ATTR diagnosis based on nuclear imaging alone—must confirm absence of monoclonal protein 1.
• The International Society for Heart Research recommends against using digoxin or calcium channel blockers in suspected cardiac amyloidosis, as these drugs bind to amyloid fibrils causing toxicity and exaggerated hypotensive responses even at therapeutic levels 3.

Evidence‑Based Findings in AL Cardiac Amyloidosis

Clinical Presentation

• Heart failure with preserved ejection fraction (HFpEF) is the typical presentation, manifesting as dyspnea, peripheral edema, and pleural effusions. 7
• Persistent elevation of cardiac troponin (T, I, or high‑sensitivity) is commonly observed. 7
• Bilateral carpal‑tunnel syndrome in the absence of rheumatoid arthritis or trauma serves as a red‑flag clue for AL amyloidosis. 7

Electrocardiographic Findings

• Voltage‑mass discordance: low QRS voltage (<0.5 mV in limb leads) despite increased ventricular wall thickness occurs in ≈ 50 % of patients with AL cardiac amyloidosis.** 8
• Pseudoinfarct pattern (Q waves in precordial leads) is more frequent than low voltage in cardiac amyloidosis. [7][8]

Echocardiographic Findings

Structural Abnormalities

• Increased atrial septal thickness is a characteristic echocardiographic feature of AL cardiac amyloidosis. 7

Functional Abnormalities

• Restrictive transmitral Doppler filling pattern with elevated left‑sided filling pressures is present in 57 % of patients and represents the hallmark of diastolic dysfunction. 7

Advanced Strain Imaging

• Reduced global longitudinal strain with an apical‑sparing pattern (apical‑to‑basal strain ratio > 2.1) is highly suggestive of cardiac amyloidosis and should be assessed in all suspected cases. 7
• An LV ejection‑fraction‑to‑strain ratio > 4 constitutes a notable diagnostic marker. 7
• Decreased longitudinal strain with preserved apical function creates a “bull’s‑eye” appearance on strain mapping. 9

Diagnostic Work‑up

• When echocardiography reveals suggestive findings, immediate monoclonal protein screening (serum and urine immunofixation electrophoresis plus serum free‑light‑chain assay) is required to confirm AL amyloidosis. 7
• Cardiac magnetic resonance imaging should be performed when echocardiographic results are equivocal; diffuse subendocardial late gadolinium enhancement (88 % sensitivity, 100 % specificity for AL) and elevated native T1 values support the diagnosis. 10

Diagnosis of Cardiac Amyloidosis – Evidence‑Based Pathways

1. Consensus‑Based Diagnostic Framework (ASNC/AHA/ASE 2021)

• The 2021 ASNC/AHA/ASE expert consensus defines three mutually exclusive pathways to diagnose cardiac amyloidosis—histologic confirmation by endomyocardial biopsy, histologic confirmation by extracardiac tissue biopsy combined with characteristic cardiac imaging, or a fully non‑invasive algorithm for ATTR that requires no tissue sampling. [11][12]

2. Histological Diagnosis

2a. Endomyocardial Biopsy

• Demonstration of Congo‑red positivity with apple‑green birefringence on polarized light in an endomyocardial specimen confirms cardiac amyloidosis for all subtypes (AL, ATTR, others). [11][12]
• Amyloid typing must be performed with immunohistochemistry and/or mass‑spectrometry at specialized laboratories, achieving approximately 88 % sensitivity and 96 % specificity. 11
• Endomyocardial biopsy remains the gold‑standard when non‑invasive imaging is equivocal or when precise tissue typing is required for therapeutic decision‑making (Class I recommendation). 13

2b. Extracardiac Tissue Biopsy

• For ATTR amyloidosis, a positive extracardiac biopsy (e.g., abdominal fat pad, gingiva, rectum, bone marrow) together with typical cardiac imaging findings establishes the diagnosis without cardiac tissue sampling. [11][12]
• For AL amyloidosis, a positive extracardiac biopsy plus either (i) characteristic cardiac imaging findings or (ii) abnormal cardiac biomarkers (elevated NT‑proBNP or troponin after exclusion of other causes) confirms the diagnosis. [11][12]
• The AHA notes that in patients with systemic amyloidosis proven in non‑cardiac tissue, echocardiographic or cardiac‑MRI features suggestive of infiltrative cardiomyopathy can support a cardiac amyloidosis diagnosis without the need for endomyocardial biopsy (Class IIa). 13

3. Non‑Invasive Diagnosis of ATTR (No Biopsy Required)

• ATTR cardiac amyloidosis can be diagnosed when all of the following are present:

4. Imaging Criteria that Support the Diagnosis

4a. Echocardiography

• Left‑ventricular wall thickness > 12 mm (after exclusion of other causes). 11
• Relative apical sparing of global longitudinal strain, defined by an apical‑to‑basal + mid ratio > 1. 11
• Diastolic dysfunction of grade ≥ 2. 11

4b. Cardiac Magnetic Resonance (CMR)

• Left‑ventricular wall thickness exceeding the sex‑specific upper limit of normal. 11
• Global extracellular volume (ECV) > 0.40. 11
• Diffuse late gadolinium enhancement. 11
• Abnormal gadolinium kinetics with myocardial nulling occurring before blood‑pool nulling. 11

5. Role of Pericardial Fluid Analysis

• Pericardial fluid is not included in any of the consensus diagnostic pathways; therefore, Congo‑red staining of pericardial fluid has no role in establishing cardiac amyloidosis. [11][12]

6. Indications to Proceed with Endomyocardial Biopsy

• When non‑invasive imaging (echocardiography, CMR, or nuclear scintigraphy) yields equivocal or inconclusive results, an endomyocardial biopsy is recommended to obtain definitive tissue confirmation (Class IIa). 13